

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board of directors (the “**Board**”) of CanSino Biologics Inc. (the “**Company**”) announces that Ms. Yuan ZHOU (“**Ms. ZHOU**”) ceased to serve as an employee representative supervisor of the third session of the board of supervisors of the Company (the “**Board of Supervisors**”) due to personal reasons with effect from November 25, 2024. Ms. ZHOU no longer holds any position in the Company after her resignation.

Ms. ZHOU has confirmed that she has no disagreement with the Board or the Board of Supervisors and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board and the Board of Supervisors expressed their gratitude to Ms. ZHOU for her contribution to the development of the Company during her tenure as an employee representative supervisor of the Company.

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board is also pleased to announce that the Company convened an employee representative meeting on November 25, 2024, during which Ms. Chang SUN (“**Ms. SUN**”) was elected as an employee representative supervisor of the Board of Supervisors. Ms. SUN’s term of office commences from the date of the resolution of the employee representative meeting until the expiry date of the third session of the Board of Supervisors.

The biographical details of Ms. SUN are set out below:

Ms. SUN, aged 33, is currently serving as the securities affairs representative of the Company. She joined the Company in June 2019 as a senior supervisor of securities affairs and has served successively as the manager and senior manager of the Company. From March 2016 to May 2019, she worked in the Investment Banking Department of Tianfeng Securities Co., Ltd. (天風證券股份有限公司), whose shares are listed on the main board of Shanghai Stock Exchange (stock code: 601162). Ms. SUN obtained her master of finance degree from Clark University in the United States in December 2015, and obtained her bachelor of economics degree from Tianjin University of Finance and Economics (天津財經大學) in the PRC in June 2014.

Ms. SUN is a participant of the 2023 A Share Employee Stock Ownership Plan approved by the Company at the 2023 first extraordinary general meeting on April 20, 2023 (the “**2023 Stock Ownership Plan**”). As of the date of this announcement, Ms. SUN is interested in 405 A shares of the Company through the 2023 Stock Ownership Plan.

Ms. SUN has entered into a service contract with the Company. Ms. SUN will not receive additional remuneration from the Company to act as an employee representative supervisor of the Company.

Saved as disclosed above, as of the date of this announcement, Ms. SUN has confirmed that she (i) does not hold any other positions in the Company or its subsidiaries; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company; (iii) has not held any directorship or supervisor positions in any listed companies in the past three years; and (iv) does not have any other interests or short positions in the shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Saved as disclosed above, as of the date of this announcement, there is no other information in respect of Ms. SUN that needs to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there is no other matter in respect of her appointment that needs to be brought to the attention of the shareholders of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 25, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.